Novel treatments for anxiety and depression: hurdles in bringing them to the market.
Anxiety and depressive disorders are the most common psychiatric conditions. The medical need for newer, better-tolerated and more efficacious treatments remains high. However, drug development is time-consuming and has a high rate of failed or inconclusive trials. Improvements in study design, investigator training and early proof-of-concept studies are being discussed as means to decrease failure rates and the duration of development. So far, no uniformly applicable 'magic formulas' for success have been discovered. The most promising approach to overcome these hurdles appears to be a sound study design carried out by experienced professionals in the clinic and in industry.
Buller
Raimund
R
3-5 Rue Maurice Ravel, F-92564 Levallois-Perret, tel: +33 1 41 27 72 17 fax: +33 1 41 27 72 00, Paris, France
Legrand
Valérie
V